MECP2 and atypical Rett syndrome: This limits the efficiency of therapeutic directed RNA editing applications where the target adenosine has a 5′ G, such as premature UGA termination codons like those arising from the R168X, R255X and R270X mutations in the MECP2 gene associated with Rett Syndrome (27).